Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Van de Werf

Showing results (1-10 of 290) with videos related to

Pageof 29
Sort By:
European Heart Journal|August 24, 1999
Streptokinase...never againF van de Werf
Cardiologia (Rome, Italy)|December 1, 1995
Acute myocardial infarctionF Van de Werf
European Heart Journal|June 19, 2002
ASSENT-3: implications for future trial design and clinical practiceF Van de Werf
European Heart Journal|December 5, 2000
In TIME-II: more than a study on lanoteplaseF Van de Werf
European Heart Journal|August 21, 2001
Why is there so much geographic variation in clinical outcome in international trials of fibrinolytic therapy?F Van de Werf
Verhandelingen - Koninklijke Academie Voor Geneeskunde Van Belgie|January 1, 1994
[The variable effect of coronary reperfusion on survival and left-ventricular function: how do thrombolytics act?]F Van de Werf
Australian and New Zealand Journal of Medicine|December 1, 1993
New thrombolytic strategiesF Van de Werf
Thrombosis and Haemostasis|July 1, 1997
Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromesF Van de Werf
Drugs|September 1, 1996
Implications of the GUSTO trial for thrombolytic therapyF Van de Werf
Australian and New Zealand Journal of Medicine|December 1, 1993
Mortality results in GUSTOF Van de Werf
Pageof 29

Showing results (1-10 of 290) with videos related to

Sort By:
Pageof 29
European Heart Journal|August 24, 1999
Streptokinase...never againF van de Werf
Cardiologia (Rome, Italy)|December 1, 1995
Acute myocardial infarctionF Van de Werf
European Heart Journal|June 19, 2002
ASSENT-3: implications for future trial design and clinical practiceF Van de Werf
European Heart Journal|December 5, 2000
In TIME-II: more than a study on lanoteplaseF Van de Werf
European Heart Journal|August 21, 2001
Why is there so much geographic variation in clinical outcome in international trials of fibrinolytic therapy?F Van de Werf
Verhandelingen - Koninklijke Academie Voor Geneeskunde Van Belgie|January 1, 1994
[The variable effect of coronary reperfusion on survival and left-ventricular function: how do thrombolytics act?]F Van de Werf
Australian and New Zealand Journal of Medicine|December 1, 1993
New thrombolytic strategiesF Van de Werf
Thrombosis and Haemostasis|July 1, 1997
Clinical trials with glycoprotein IIb/IIIa receptor antagonists in acute coronary syndromesF Van de Werf
Drugs|September 1, 1996
Implications of the GUSTO trial for thrombolytic therapyF Van de Werf
Australian and New Zealand Journal of Medicine|December 1, 1993
Mortality results in GUSTOF Van de Werf
Pageof 29